Developing a Solution to Cure Corneal Blindness

Limbustem is a company developing an innovative therapy for limbal stem cell deficiency (LSCD), which can cause corneal blindness. Their product, Limbustem PRO AMEX, is an in vitro cultured limbal epithelial cellular therapy aimed at restoring vision and improving patients' quality of life. With over 15 years of research, Limbustem's therapy is designed to be more affordable than existing options, making it accessible to more patients. The product is currently preparing for market entry in Europe after successful trials in Türkiye.

Meet the Team

The team management consists of 2 co-founders; Asssoc Prof Dr Ozlem Barut Selver, MD and Dr Mehmet Gurdal, PhD

Dr. Selver is an cornea  specializing ophthalmologist. She worked as a specialist at Ege University Faculty of Medicine, Department of Ophthalmology, between 2014-20, and has been working as an Associate Professor at the same institution since 2020.

Dr. Gurdal is a bioengineer with a PhD specializing in the field of tissue engineering. He has over 10 years of experience in engineering of corneal cells in vitro, worked on corneal bioengineering as a postdoctoral researcher at University College Dublin between 2018- 22.

The two co-founders have been working multidisciplinary for over 15 years and they have carried out 10 research projects, won 5 prices & awards, published over 15 papers in international journals. Thanks to this strong academic background and harmonizing their extensive clinical and engineering skills, the team introduced their first tissue-engineered advanced therapy product as an MVP to the local market within the 3rd year of establishment of the spin-off company.